1. Scrip
  2. >>Business

Podcast: Cell Therapy Firm Stempeutics' CEO On Japan Partnerships, India Trials Regulation Changes

 
• By Vibha Ravi

CEO of cell therapy firm Stempeutics BN Manohar speaks to Scrip about partnering with Japanese firms for India’s first allogenic cell therapy Stempeucel. Amid a tough funding environment, AI and new manufacturing tech will drive savings as the company pursues new indications and changes in Indian regulation on clinical trials could make the CGT journey easier, he says in the interview.

Scrip Podcast Special
Stempeutics CEO BN Manohar Speaks To Scrip

Stempeutics Research Pvt. Ltd. commercialized India’s first allogenic stem cell therapy Stempeucel after the Drugs Controller General of India granted manufacturing and marketing approval for treatment of Critical Limb Ischemia (CLI) due to Buerger’s disease and CLI due to atherosclerotic peripheral arterial disease.

The Mesenchymal Stromal Cells (MSCs) product was later also approved in India to treat knee osteoarthritis (OA) and diabetic foot...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

Bayer’s Kerendia Gains Blockbuster Indication For Heart Failure

 
• By Joseph Haas

New US approval in heart failure with preserved or mildly reduced ejection fraction should add to Kerendia’s earning power on top of chronic kidney disease indication.

Takeda Prepares Ground For Oveporexton In Narcolepsy

 
• By Alaric DeArment

The drugmaker announced positive results from two Phase III trials for the drug in narcolepsy type 1 that analysts said bode well for the OX2R agonist class as a whole.

Leo Lands Another Big Pharma Pact With Boehringer Spevigo Deal

 
• By Kevin Grogan

Paying €90m upfront for rights to generalized pustular psoriasis drug.

Quick Listen: Scrip’s Five Must-Know Things

 
• By Ian Haydock

In this week's episode: Merck & Co’s Verona acquisition; venture funding plummets in Q2; how Teva is expanding innovation; Apogee’s Phase II eczema win; and a look at India’s wave of licensing.

More from Scrip

Pipeline Watch: Ten Approvals And Two Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Quick Listen: Scrip’s Five Must-Know Things

 
• By Ian Haydock

In this week's episode: Merck & Co’s Verona acquisition; venture funding plummets in Q2; how Teva is expanding innovation; Apogee’s Phase II eczema win; and a look at India’s wave of licensing.

Capricor Gets Complete Response For DMD Cell Therapy

 
• By Joseph Haas

Seven weeks before its action date, Capricor got an FDA complete response for cell therapy deramiocel in DMD-related cardiomyopathy. It has a Phase III study nearing readout, though.